LISTINGS POSTER
Search using the Ctrl+F keys
| Id | First Name | Last Name | Title |
| A Special Populations Safety: 1 Newborn and pediatric patients | |||
| 10 | Marcela | Rousseau | Potential risk factors in the development of drug-related problems in complex chronic pediatric patients |
| 44 | Lobna | Kilany | Seizures in Breast-fed Infants Following Maternal Use of Dicyclomine-Containing Product: National case reports highlight spontaneous reporting and risk minimization importance |
| 61 | Cristina | Fernandez | Nirsevimab Safety Monitoring in Neonates: A National Approach |
| 89 | Helfrid | Ilomo | Prevalence of Acute Kidney Injury and Nephrotoxic Drug Exposure in Premature and Low-Birth-Weight Neonates Admitted to Intensive Care Units. |
| 161 | Oumaima | EL QABISSI | Prevention of Aspiration During Vitamin D Supplementation: Analysis of 6 Months of Pharmacovigilance Data. |
| 286 | Bryan | Ata Calixto | Understanding therapeutic failure of tacrolimus in pediatric kidney transplantation: a pharmacovigilance‑driven narrative review. |
| A Special Populations Safety: 2 Womens Medicine and Maternal Health | |||
| 67 | Sara | Hedfors Vidlin | Pregnancy Exposures in VigiBase: Report Retrieval and Information Extraction Using Large Language Models |
| 74 | Maria Guadalupe | Garcia Darderes | Perinatal Outcomes In Pregnancies Exposed To Elexacaftor/Tezacaftor/Ivacaftor (Trixacar) According To Maternal CFTR Genotype: Post‑Marketing Experience. |
| 138 | Sara | Hedfors Vidlin | Pregnancy Exposures in VigiBase: A Descriptive Overview of the Last 20 Years |
| 139 | Lovisa | Sandberg | Pregnancy Exposures in VigiBase: Aspects of Quality and Reporting Challenges |
| 204 | Aleyda | Sánchez | Consistency of safety information on labeling for the use of psychotropic drugs during pregnancy |
| 234 | Dima | Qato | Trends in the use of prescription medications among women of reproductive age by pregnancy status in the US, 2009–2020 |
| 307 | Diana | Delgado | Evaluation of the prophylactic use of antibiotics in cesarean section |
| A Special Populations Safety: 3 Older Patients | |||
| 140 | Veronika | Lykholat | Improving Awareness of Iatrogenic Dependency Prevention in Older Adults |
| 160 | Veronika | Lykholat | Improving Awareness of Medication-Related Iatrogenesis in Older Adults |
| 167 | Sofia | Segura Cano | Potentially Inappropriate Medication Use Among Older Adults in Costa Rica: Evidence from the Nationally Representative CRELES Survey |
| 193 | Fátima | Roque | Understanding iatrogenesis: a thematic analysis of healthcare professionals’ perspectives |
| 198 | Sofia | Segura Cano | Translating National Survey Data into Usable Pharmacoepidemiologic Evidence: Methodological Considerations from Costa Rica |
| A Special Populations Safety: 4 Oncology Patients | |||
| 13 | Brahim | Azzouz | Progressive Multifocal Leukoencephalopathy risk and epcoritamab exposure : WHO pharmacociviglance analysis and literature data |
| 77 | Sophia | DOUKALI | Toward Integrated Value Assessment of Innovative Cancer Therapies: Quality of Life, Safety, and Socioeconomic Impact – A Preliminary Analysis |
| A Special Populations Safety: 5 Immunotherapy | |||
| 191 | Francoise | Livio | Immune Checkpoint Inhibitor-Associated Myositis With Myasthenia Gravis-Like Presentation And Myocarditis |
| 238 | Ala | Ali | Renal Safety of Immune Checkpoint Inhibitors in Iraqi Cancer Patients: Incidence, Timing, and Risk Factors of Acute Kidney Injury |
| 264 | Maxime | Demourgues | Immune-Related Adverse Events associated with Immune Checkpoint Inhibitors: Analysis of Cases Discussed at an Expert Immunotoxicity Board |
| E Culture, trust and ethics: 2 Building Trust Among Stakeholders | |||
| 20 | Myeoong-eun | Cheon | Structural Distrust as a Pharmacovigilance Failure: LLM-Based Analysis of Vaccine Hesitancy Discourse Following a Government Audit Disclosure in South Korea |
| 224 | C. Gelida | Barboza Justiniano | Shaping the Future of Pharmacovigilance in Peru: Lessons from the Second Student Meeting and MedSafetyWeek |
| 274 | Daniela Vianey | Rosas Villa | Operational Challenges in Evaluating the Impact of Antibiotic Use on Gut Microbiota in Pediatric Acute Lymphoblastic Leukemia: Implications for Pharmacovigilance |
| 296 | Carlos | Pizarro | Symmetric Communication as a Pillar of Trust: A Bioethical Approach of Patient Participation in Pharmacovigilance in the Global South |
| B Digital transformation & AI in Pharmacovigilance: 1 AI Applications and responsible use | |||
| 4 | Myeoong-eun | Cheon | Vax-Beacon Global: A Neuro-Symbolic Hybrid Architecture for Privacy-Preserving and Mechanistically Grounded Vaccine Safety Surveillance with Automated Field Guidance |
| 84 | MABEL EDITH LAURA | MAUCAILLE ROJAS | Designing Structured Prompts to Support AI‑Assisted Preliminary Assessment of Adverse Event Cases |
| 86 | Francisco | de la Peña-Solís | Integrating Disproportionality Metrics with Machine Learning Improved Antibiotic Safety Signal Detection: a retrospective cohort study on Mexican Haemato-Oncology Pediatrics |
| 146 | Jan | Petracek | From Human-Only to AI-Mostly PV organisation: A Real-World Implementation Journey Towards Scalable, Trustworthy Safety Operations |
| 156 | Estella | Zamora Calero | Integrating Generative AI into Post‑Marketing Pharmacovigilance: A Risk‑Based, Human‑in‑the‑Loop Approach for ICSR Processing |
| 233 | Dima | Qato | Polypharmacy and Drug Combinations Associated with Unintentional Drug Overdose in the United States |
| 235 | Kenenisa Tadesse | Dame | Fine-Tuned Biomedical Transformers to Verify MedDRA Coding Related to Guillain–Barré Syndrome in Individual Case Safety Reports Database. |
| 236 | Osvaldo | Mondragon Frias | Zero-Shot Prompting for Causality Assessment in Pharmacovigilance: Pilot Study on Myocarditis Following mRNA COVID Vaccines |
| 254 | Niklas | Norén | A probability-anchored AI system for second-line adjudication of suspected duplicate reports in pharmacovigilance |
| 256 | Mario | Durán Quirós | From searching to answering: SOPilot’s time impact and trust controls for PV procedural questions |
| 260 | Lelio | Crupi | Performance of an NLP‑Driven System for Identifying High‑Severity Potential Drug–Drug Interactions at Hospital Discharge |
| B Digital transformation & AI in Pharmacovigilance: 2 Digital tools | |||
| 16 | Sonia | Corbin | The DECLARE Platform: A Structured Database Dedicated to Pharmacovigilance |
| 46 | Jacinthe | Leclerc | The DECLARE-IUCPQ-ULaval database: a goldmine to address underreporting of adverse events |
| 79 | MARIA VICTORIA | TOURN | Design, Development and Implementation of an In-Company AI Agent for the Elaboration of PBRERs (ICH E2C (R2) format) |
| 109 | Guillermo | Keller | Evaluation of the implementation of electronic records in the identification of adverse reactions as causes of admission. |
| 162 | Asmau | Abubakar | Evaluating Industry ADR E-Reporting Tool for Marketing Authorization Holders (MAHs) Integration with VigiFlow in Nigeria (2024–2026) |
| 207 | Paola | Acuna | Tackling Increasing Challenges in Clinical Trial Safety Operations: Navigating Enhanced Protocol Complexity and Variations in Reporting Timelines to Health Authorities |
| 225 | Helfrid | Ilomo | Enhancing Pharmacovigilance and Clinical Pharmacy Services Through VigiSafe: Outcomes from a Three-Month Implementation Study at Muhimbili National Hospital, Tanzania. |
| 277 | Valeria | Facciolo | Human-In-The-Loop Conceptual Framework for Medication Errors Detection in ICSR Processing Designed to Support Pharmacovigilance Systems in Low- and Middle-Income Countries |
| 289 | Mercedes | Leburu | Closing the Global Pharmacovigilance Data Gap: Building Unified, Africa-Centric Data-Driven Drug Safety Ecosystem through AfriVigilance Platform under African Medicines Agency |
| 293 | Barbara | Figueroa | Applying Artificial Intelligence (AI) to Strategic Pharmacovigilance Activities: Evidence from Local Medical Literature Screening |
| 298 | Yesenia | Rodríguez | Implementation of an Electronic Health Record Pharmacovigilance System in Peru: Trends, Reporter Characteristics, and Adverse Drug Reaction Profiles, 2022–2025 |
| C Risk management: 1 Risk Communication | |||
| 17 | Pfunzo Collins | Mukoma | Title: Risk Communication in Pharmacovigilance: Communicating Safety Signals Clearly Without Causing Panic or Misinformation |
| 82 | Antonio | Lomeli Silva | The Nocebo Effect in Pharmacovigilance: Impact of Safety Alerts on the Reporting of Subjective and Objective Adverse Drug Reactions |
| 108 | Guillermo | Keller | Evaluation of a safety surveillance program for the use of thrombolytics in an Emergency Department |
| 115 | Lily | Chan | Impact of Regulatory Actions on the Awareness of Risks Associated with Use of Antiepileptic Medicines During Pregnancy |
| 164 | Thomas | Stammschulte | Approaches for improved risk communication in Switzerland |
| 184 | Maria | Cleonice | Safety alerts as tools for risk communication: a retrospective study by the Brazilian Health Regulatory Agency from 2020 to 2026 |
| 211 | Cinthya | Galicia | Safe Access: A Strategic Alliance with Insurance Companies to Protect Patients from Falsified Medicines in Mexico |
| 310 | Laura | Sottosanti | Enhancing the effectiveness of safety communication: a regulatory approach to the introduction of an official pictogram for DHPCs in Italy |
| C Risk management: 2 Benefit- risk Assessment | |||
| 55 | Lunara | Silva | Labeling Updates Requested by the Brazilian Pharmacovigilance Office: an Analysis of Routine Post-marketing Surveillance in 2025 |
| 78 | Marion | ALLOUCHERY | Safety Burden of Serious Drug-Drug Interactions: A 10-Year Regional Study using the French National Pharmacovigilance Database |
| 110 | Guillermo | Keller | Evaluation of the risk-benefit ratio of antivenom use based on the severity of the clinical picture of scorpion sting cases. |
| 113 | Gita | Toyserkani | Rapid Qualitative Methods to Identify Multi-Level Barriers to Early Benefit-Risk Integration in Pharmacovigilance Systems: A Multi-Stakeholder Customer Discovery Study |
| 228 | viviana | martinez garcia | Patient-reported satisfaction with subcutaneous treprostinil in pulmonary arterial hypertension |
| C Risk management: 3 Risk Minimisation Methods and Policies | |||
| 22 | Mark | Perrott | Patient engagement in the development of a digital risk minimisation tool to enhance value and support effectiveness |
| 57 | Jean-Christophe | Delumeau | ISoP SiG Risk Minimisation Methods 2026 initiative: Addressing Routine Risk Minimisation Gaps for Medications with Safety Concerns. |
| 59 | Javier | Sawchik | Effectiveness of Additional Risk Minimisation Measures for Valproate in Belgium: A Follow-Up Cross-Sectional Survey of Women of Childbearing Potential |
| 68 | Ella | van Vliet | Integrated Barriers, Enablers, and Policy Recommendations for the Implementation of Risk Minimisation Control Programmes in the EU |
| 69 | Marie L | De Bruin | A cross-national analysis of Risk Minimisation Control Programs and Regulatory Implementation pathways in Eight EU Countries |
| 70 | Sharon | Essink | Implementation and Use of Risk Minimisation Control Tools in the EU: a Multistakeholder Survey |
| 72 | Sharon | Essink | Discontinuation of Additional Risk Minimisation Measure Tools for Centrally Authorised Medicinal Products in the EU |
| 75 | Maria Guadalupe | Garcia Darderes | Post‑Marketing Safety Experience Of Elexacaftor/Tezacaftor/Ivacaftor (Trixacar – Trixacar P): Alignment Between The RMP And Reported Cases Since Commercialization. |
| 91 | tamanna | ghosh | Blood dyscrasia in leprosy due to dapsone: A series of four cases |
| 181 | Diana | Gonzalez | Regulatory Processes for the Approval of Risk Management Plans in Seven Latin American Countries: Implications for Regional Pharmacovigilance Harmonization. |
| 187 | Pamela | Ramírez | Effectiveness and Implementation of Patient Support Programs for Additional Risk Minimization Measures:A Global Systematic Review with Focus on LATAM |
| 263 | Maxime | Demourgues | Prevalence and Preventability of Adverse Drug Reactions Related to Toxic Anti-Infective Levels: a pilot study. |
| D Regulatory science and PV systems: 1 Harmonization | |||
| 80 | Carlos | Fernandez | Bridging Gaps in Risk Management Plans Across Latin America: From Academic Research Project to a Regional Pharmacovigilance Handbook |
| 123 | Jhojan Jesús | Ugarte Chinchero | Pharmacovigilance of Medicinal Cannabis in Latin America: Advances, Gaps, and Regulatory Challenges. |
| 189 | Tábatha Renée | Ponce de León Miranda | Proposal for a Checklist for Audits and Inspections in Pharmacovigilance as a Tool for the Pharmaceutical Industry in Mexico |
| 205 | Maria | Araya | Integrating clinical Electronic Data Capture (EDC) Platforms with Safety Systems: Benefits and Challenges |
| D Regulatory science and PV systems: 2 Reliance and Worksharing | |||
| 136 | Michele | Fusaroli | Open-Source in Pharmacovigilance: Demonstrating a Reproducible Workflow Using the FDA Adverse Event Reporting System |
| 186 | Diana | Gonzalez | Impact of the WHO Global Benchmarking Tool on Pharmacovigilance in Latin America: From PAHO Regional Certification to a Global Framework |
| 223 | Sandra | Mendoza | From Insight to Impact: Enhancing Pharmacovigilance Operations Through Reliance- and Worksharing-Driven Process Innovation |
| D Regulatory science and PV systems: 3 PV policies, transparency and governance | |||
| 27 | Ibrahim | Amidu | Evaluation of Pharmacovigilance Systems and Factors Influencing Adverse Drug Reaction Reporting in Military Healthcare Facilities in Southwest Nigeria |
| 40 | Dr Alhagie Mutarr | Bah | Strengthening Pharmacovigilance Systems through Regulatory Science: Building Ecosystems of Trust in The Gambia |
| 54 | Tatiana | Cruz González | Hybrid Multilevel Comprehensive Assessment Instrument of National Pharmacovigilance Systems: Advancing Trust Ecosystems, Governance, and Regulatory Performance |
| 251 | Ban Abdulameer | Al-Shimran | Adaptive Evolution of the Annual Evaluation Framework for Regional Pharmacovigilance Centers in Iraq Over the Years |
| D Regulatory science and PV systems: 4 Regulatory affairs | |||
| 63 | Gabriela | Jure | Beyond Bioequivalence: Clinical Challenges of Antibiotic Interchangeability in Vulnerable Patients |
| 267 | Alfredo | Barrera | From Regulation to Inspection: A Comparative Analysis of Pharmacovigilance Inspection Checklists in Latin America |
| F Evidence generation, Pharmacoepidemiology and Signal Management: 1 Real World Evidence and Big Data | |||
| 9 | Jefferson Santiago | Piedra Andrade | Real-world determinants of mortality after ischemic stroke: implications for pharmacovigilance of thrombolytic therapy in a Ecuadorian cohort |
| 23 | Fabiana | Varallo | Safety and effectiveness of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in HFpEF: a systematic review of real-world studies |
| 60 | Fabiana | Varallo | Lithium-related medication errors: findings from the Brazilian VigiMed pharmacovigilance database |
| 62 | Geovana | Schiavo | Adverse events to Z-Drugs in older adults in Brazil: analysis of VigiMed data |
| 112 | Cristina | Ruas | Real-world pharmacovigilance profile of cannabis-based products in France: analysis of a national surveillance database |
| 222 | Melisa | Naranjo | Real-World Evidence: Experiences, Challenges, and Opportunities for Decision Making in Latin America, Central America, and the Caribbean |
| 240 | Laís | Beanucci Coelho | Completeness of individual case safety reports for GLP-1 receptor agonists in the Brazilian VigiMed database: a pharmacovigilance study |
| 241 | Laís | Beanucci Coelho | Comparative disproportionality analysis of acute pancreatitis reports among GLP-1 receptor agonists: a pharmacovigilance study using the Brazilian VigiMed database |
| 261 | Inês | Tavares | Two Sides of the Same Pen: A Real-World Disproportionality Analysis of Semaglutide by Therapeutic Indication |
| F Evidence generation, Pharmacoepidemiology and Signal Management: 2 Pharmacoepidemiology | |||
| 26 | Vanessa | Gomes | Trismus related with antidepressant use worldwide: a disproportion analysis from 2015 to 2025 |
| 51 | Fabiana | Varallo | Opioids in Science and Public Health: A Global Bibliometric Review of Trends, Inequities, and Emerging Research Frontiers |
| 116 | Yesenia | Rodríguez | Comparative Post-Marketing Risk of Aneurysm and Dissection After Intravitreal Aflibercept vs Bevacizumab: A Target Trial Emulation Study |
| 179 | Luis | Velez | Treatment rates for glaucoma and intraocular hypertension in the United Kingdom, 2000-2022 |
| 255 | Tony | Hama | Conscientious Numerator-Denominator Design for Trustworthy Pharmacoepidemiology in Low-Resource Settings |
| 299 | Danya | Qato | From Baltimore to Costa Rica: Advancing Pharmacoepidemiology of Aging Research Through International Collaborations |
| F Evidence generation, Pharmacoepidemiology and Signal Management: 3 Signal management | |||
| 43 | Mona | Aboelseoud | Potential Signal of Ocrelizumab Administration and Angina Pectoris: A Review of the WHO Global Database and Literature Search |
| 45 | Lobna | Kilany | Morphoea Profunda in an Infant Following Hepatitis B Vaccination: A National Case Report Highlighting Real-World Evidence and Risk-Minimization Strategies |
| 83 | Homero | Contreras Salinas, PhD | Regulatory compliance in pharmacovigilance data mining: a structured framework for critical appraisal of signal detection studies. |
| 117 | Julia | Scheuring | A Systematic Literature Review of Signal Detection Methods |
| 142 | Michele | Fusaroli | Towards a More Effective Triage Pipeline for Safety Signals: Exploring Historical Reasons for Early Dismissal |
| 147 | Michele | Fusaroli | Early Dismissal of Signals Affected by Indication-Related Biases: Evaluation of Reverse-Causality and Confounding-by-Indication Filters in Vigibase |
| 154 | Ylva | Haasum | Time to Consider: Long Time-To-Onset in VigiBase |
| 165 | McKenna | Anderson | From Static Signal to Longitudinal Narrative: A Retrospective Case Study of Ketamine-Induced Cystitis Using Quarterly Disproportionality Analysis |
| 231 | Veselinka | Vukicevic | Retching and Nausea related to Azelastine Eye Drops – Patient's Contribution to Signal Detection |
| 276 | Asmau | Abubakar | Developing a National Signal Management Framework in Nigeria: Progress, Challenges, and Lessons from a Low- and Middle-Income Setting |
| 282 | Mercedes | Leburu | Strengthening Continental Signal Management in Africa: Early Experience from a novel Signal Validation Hub Model |
| 312 | Chelsea | Möller | Assessability of ICSRs In VigiFlow From Namibia (2024-2025): A Retrospective Analysis Of Minimum Data Requirements For WHO-UMC Causality Assessment |
| G Medication Errors: 1 Medication Errors Risk Mitigation | |||
| 175 | Pamela | Nambwa | Medication Errors due to Look-Alike Sound-Alike Medicines in Kenya |
| 197 | Fernanda | Marfil | Preventing medication errors at home: immersive and age adapted educational interventions to promote safe medication storage in South America |
| 252 | Doaa | duaaadnan714@gmail.com | Using National Pharmacovigilance Data to Prevent Amiodarone-Related Harm in Iraq, 2015-2025 |
| G Medication Errors: 2 Coordinated Actions for Medication Errors Management | |||
| 2 | Lubna | Merchant | Optimizing Product Design, Labeling, and Packaging to Minimize Medication Errors: A Systems-Based Approach Across the Product Lifecycle |
| G Medication Errors: 3 Policies, Regulation and Government Actions in Medication Errors | |||
| 32 | Aleksandra | Schwarzrock-Fabian | Does dosing information on prescriptions improve medication safety? Comparison of two surveys among German community pharmacists in 2023 and 2025 |
| 133 | Evelien | De Clercq | Medication Errors Involving RSV Immunisation Products in Belgium: A Pharmacovigilance Case Review and Regulatory Response |
| 245 | Allan | Serwanga | Evaluation of Uganda’s Framework for the Prevention and Reporting of Medication Errors: Opportunities and Challenges |
| 275 | Abeer | Zeitoun | When Systems Exist but Reporting Culture Fails: Bridging the Engagement Gap in Medication Error Reporting |
| 292 | Jhojan Jesús | Ugarte Chinchero | Digital pharmacies and delivery services in Latin America: emerging risks of medication errors and patient safety |
| G Medication Errors: 4 Medication Error Case of Study | |||
| 311 | Eunicke | Heitha | Medication Error Reporting in Namibia: A Retrospective Review of VigiFlow Reports from January 2024 to April 2026 |
| H Medical Devices: 1 Medical Devices Risk Mitigation | |||
| 297 | Sumatha | Kondabolu | AI-enabled Medical Devices and Post-Market Risk: Identifying Gaps and Practical Adaptations for Inspection Readiness |
| H Medical Devices: 2 Combined Drug-Medical Devices Safety | |||
| 290 | Jhojan Jesús | Ugarte Chinchero | The new regulatory frontier: safety of drug–device combination products in Latin America |
| H Medical Devices: 4 Policies, Regulation and Government Actions in Medical Device Safety | |||
| 15 | Rachel | Mujawimana | Strengthening Patient Safety Through Regulatory Actions in Medical Device Vigilance |
| 199 | Adela | Ashie | Baseline Assessment of the Medical Device Vigilance in Ghana |
| 213 | Carlos Jesús | Rodríguez Escárcega | Contrast Media and Patient Safety: A Gap in Mexican Regulations? |
| 217 | Luis Carlos | Estrada Petrocelli | Strengthening capacities in medical devices with implications for safety: a perspective from a multisectoral initiative in Panama |
| 257 | Jhojan Jesús | Ugarte Chinchero | From Quality Complaint to Risk Signal: The Strategic Role of Technovigilance in Medical Devices in Latin America |
| 287 | Jhojan Jesús | Ugarte Chinchero | Breaking the silence: Underreporting of adverse medical device incidents in Latin America and its implications for patient safety |
| I Wider PV horizons: 1 Advanced Therapy Medicinal Products | |||
| 73 | Philipp | Berg | Causality assessment of suspected adverse drug reactions associated with advanced therapy medicinal products |
| I Wider PV horizons: 2 Pharmacogenomics | |||
| 29 | Lesly Yanira | Xajil Ramos | CYP3A5 pharmacogenomics to improve tacrolimus safety: a proactive pharmacovigilance strategy in kidney transplantation |
| I Wider PV horizons: 3 Herbal and Traditional Medicines | |||
| 19 | Pfunzo Collins | Mukoma | Title: Pharmacovigilance for Herbal and Traditional Medicines: Addressing Safety Monitoring Gaps in Widely Used Non-Conventional Therapies |
| 25 | Lobna | Gharaibeh | Beyond Tradition: Public Knowledge, Attitudes, and Practices Toward Therapeutic Cupping in Jordan |
| 242 | Victoria | Hall | Natural products and patient information: Contributions of Costa Rica’s National Drug Information Center (CIMED) between 2025 and 2026 |
| 244 | Jo | Barnes | Exploring Consumer Perspectives on Industry Roles in Pharmacovigilance for Natural Health Products: An Interview Study. |
| I Wider PV horizons: 4 Selfcare and Cosmetic Products Vigilance | |||
| 52 | Daniel | Mota | Cosmetic Safety Alerts in the European Union Rapid Alert System (2023–2025): Trends and Implications for Brazil’s Cosmetovigilance System |
| 85 | Victoria | Hall | Teaching Innovation in Dermocosmetics: Experience of a Self-Directed Virtual Course |
| 88 | Daniel | Mota | National Cosmetovigilance in Brazil: Regulatory Reform, Governance, and Early Results |
| 104 | Tamara | Gonçalves | Systemic absorption of chemical UV filters: implications for cosmetovigilance and risk management in vulnerable populations |
| I Wider PV horizons: 5 Eco Pharmacovigilance | |||
| 169 | Fernanda | Marfil | From Awareness to Action: A Multidisciplinary Eco Pharmacovigilance Approach to Medication Disposal in South America |
| 239 | Dima | Qato | Trends in Prescription Fills and Out-of-Pocket Costs of Inhaler Devices by Global Warming Potential in the US |
| I Wider PV horizons: 6 Biological and Biosimilars | |||
| 28 | Kristina | Pavlovska | The Role of Proactive Therapeutic Drug Monitoring of Infliximab in Patients with Inflammatory Bowel Disease |
| 111 | Guillermo | Keller | Evaluation of the classification of adverse reactions in a registry of reactions to therapeutic serums (antivenoms) |
| 305 | Mauricio | Torres | Institutional Transition to Biosimilar Rituximab in Diffuse Large B-Cell Lymphoma: Real-World Evidence of Safety, Clinical Response, and Survival in Colombia |
| J Vaccines & Public Health: 1 Vaccine Safety | |||
| 42 | hammad | ali | What are Brighton Collaboration (BC) Case Definitions (CD) Companion Guides (CG) and how can they be used for vaccine safety? |
| 64 | Laís | Beanucci Coelho | Adverse Events Following Immunization and Immunization Errors Reported in Brazil Between 2021 and 2024: Analysis of e-SUS Notifica Data |
| 90 | George | Sabblah | Safety of nOPV2 Vaccine among Children Under Five: Findings from Spontaneous and Cohort Event Monitoring in Ghana |
| 148 | Abdulazeez | Yahya | Active Surveillance of AESI Following Multivalent Meningococcal Conjugate Vaccine (MMCV) Outbreak Response Vaccination in Selected States in Nigeria |
| 174 | Shelly | Karuna | Brighton Collaboration/SPEAC BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Vaccine Profiles: Resources for Accessible, Standardized, Essential Vaccine Safety Information |
| 178 | Ntale | Ismail | Characterizing Adverse Events Following Immunization (AEFI) Reports in 2025: Role of Patient Reporting in Vaccine Safety Monitoring |
| 201 | Eileen | Farnon | The Brighton Collaboration’s SPEAC Project Educational Resources for Vaccine Safety |
| 230 | Asmau | Abubakar | Building trust in vaccine safety: knowledge, attitude, and practice of mothers/caregivers on immunization and AEFI reporting in FCT, Nigeria |
| 247 | Pauline | Herault | Impact Of The School Vaccination Campaign On The Profile Of Spontaneous Notifications Of Human Papillomavirus 9-valent Vaccine (Gardasil 9®) |
| 266 | Twaha | Ssebyala | Real-World Safety Monitoring of the Malaria Vaccine in Uganda: Insights from the First Year Post-Introduction |
| 283 | Edinam | Agbenu | External Quality Control of Causality Assessment of Adverse Event Following Immunization from 2021 to 2026 in West and Central Africa |
| J Vaccines & Public Health: 2 Community Pharmacovigilance | |||
| 143 | Nicky | Lubaki | Adverse Events Following Immunization During Covid-19 Mass Vaccination Campaigns In The Democratic Republic of Congo: Findings From Active Safety Surveillance |
| J Vaccines & Public Health: 3 Hospital Pharmacovigilance | |||
| 129 | Arianna | Bonaldo | Deliberate Self-Poisoning with Medicines: A Two-Year Retrospective Study in an Italian Emergency Department |
| 141 | Kemo | Kalasi | Combating challenges with resource limitations: Complimenting Regulator-led PV system with Facility-led PV systems. |
| 209 | Catalina | Zapata | Hypokalemia in Hospitalized Patients: Medication Exposure and Comorbidity Patterns Identified through Trigger-Based Surveillance |
| 248 | MARTHA | AJULONG | ASSESSING THE SERIOUSNESS OF ADVERSE DRUG REACTIONS FOLLOWING MALARIA VACCINATION AMONG INFANTS OF SIX MONTHS AT LUWERO GENERAL HOSPITAL |
| 280 | Julia J. | Segura-Uribe | Analysis of Aminoglycoside Consumption in a Tertiary Care Pediatric Hospital in Mexico |
| 300 | María | Cerrud | Active Pharmacovigilance of Antibiotic-Related Pharmaceutical Interventions in Hospitalized Pediatric Oncology Patients |
| J Vaccines & Public Health: 4 Antimicrobial Resistance | |||
| 105 | Hager | Saleh | From Evidence to Action: A Framework for Integrating Pharmacovigilance Databases into Antimicrobial Resistance Surveillance |
| 295 | Ahmed | Sami | Standardizing Antimicrobial Resistance Reporting Terminology in Iraq: Impact of National Coding Strategy on Signal Quality in a Spontaneous Reporting System |
| J Vaccines & Public Health: 5 Other Problems/conditions in Public Health | |||
| 24 | Lobna | Gharaibeh | Knowledge, Attitudes, and Practices Toward Weight-Loss Medications Among University Students in Jordan |
| 76 | Mwesigwa | Douglas | One Year After Introduction of the Malaria Vaccine into Uganda’s Routine Immunization Schedule: Early Impact and Public Health Implications |
| K Regional Advances in Pharmacovigilance: 1 ISoP Chapters Advances | |||
| 100 | Faha | Shamim | Ecosystems of Trust: Advancing Pharmacovigilance for a Healthier World |
| 284 | C. Gelida | Barboza Justiniano | Assessment of Knowledge Acquisition and Participant Satisfaction in the Latin American Pharmacovigilance Encounter 2024: A Multi-National Cross-Sectional Survey Study |
| K Regional Advances in Pharmacovigilance: 2 Local Experiences | |||
| 39 | AUSTINE | Opiata | Strengthening post-marketing surveillance through Fiel-Based Medicine Quality Screening : Experience with The GPHF Minilab in Africa Health systems |
| 103 | Luisa | Cordero | LATAM Regional Experiences in Advancing Patient Safety Culture Through World Patient Safety Day Activities (2023-2025) |
| 119 | Carlos | Diaz Tufinio | Does Ethnicity Matter? Quetiapine Adverse Drug Reaction Profiles in Bioequivalence Studies as Pharmacovigilance Tool: A Regional and International Comparative Analysis |
| 182 | Centro Guatemalteco | de Información de Medicamentos | Professional Development Program on Pharmacovigilance offered by CEGIMED |
| 188 | Centro Guatemalteco | de Información de Medicamentos | Pharmacovigilance Service provided by the CEGIMED Sentinel Center |
| 212 | Yatziry | Rojano Avalos | Recognizing to Prevent: Drug-Induced Dermatosis and Its Clinical Impact |
| 229 | AUSTINE | Opiata | Strengthening Pharmacovigilance through Medicine Quality Surveillance: Lessons from Faith-Based Health Supply Chains in Sub-Saharan Africa |
| 232 | Juan | Maskin | Strengthening Pharmacovigilance in Argentina: Institutional Consolidation and Strategic Development of the Argentine Association of Pharmacovigilance – AsAF |
| 253 | Catalina | Lizano | Integrating Patient-Reported Outcomes Measures into Pharmacovigilance: Development of an instrument to identify barriers/enablers to their use in Costa Rica |
| L Patient Development: 1 Patient Engagement and Empowerment | |||
| 170 | Fernanda | Marfil | Co‑creating Unbranded Educational Materials with Patient Organizations to Support Safe Use of Medicines: A Patient‑Centric Pharmacovigilance Initiative |
| 195 | Lincoln | Marques | Assessment of Patient-Led Causality Attribution for Suspected Adverse Drug Reactions in Drug-Resistant Epilepsy |
| 208 | Fernando | Pastrana | Partnership with patient association for patient safety and adverse events awareness |
| 214 | Isabel | Hernandez Romo | The Value of Direct Patient Reports in Industry Pharmacovigilance: A Key Source for Understanding the True Impact of Medications. |
| 258 | Jhojan Jesús | Ugarte Chinchero | Direct Patient Reporting in Latin America: Opportunities to Strengthen Pharmacovigilance and Technovigilance |
| 278 | Abeer | Zeitoun | Building Trust in Medication Safety During Crises: Strengthening Pharmacovigilance Ecosystems in Lebanon |
| 291 | Comfort | Ogar | Empowering Patients in Medication Safety: From Passive Recipients to Active Partners in Pharmacovigilance |
| 304 | Emily | Arcos Constante | Validation of the “Soltar el Freno” Digital Model for Pharmacovigilance, Pharmaceutical Care, and Patient Empowerment in Pharmacotherapy |
| L Patient Development: 3 Education for patients | |||
| 121 | chay | lee | Pharmacotherapeutic follow-up in an older adult patient with high risk of adverse drug reactions |
| 216 | Ana Karen | Verduzco | Impact of the “¡REPORTA Y APORTA!” Pharmacovigilance Reporting Campaign on Individual Case Safety Reporting in a Mexican Marketing Authorization Holder |
| 306 | Maria Laura | Bonilla Acosta | Pharmacovigilance Information and Education Actions from the National Drug Information Center of Costa Rica (CIMED) in the Last 5 Years |
| L Patient Development: 4 Other actions for patients | |||
| 92 | Renata | Yoshida | Humanizing Pharmacovigilance: Doing More for Patients by Enhancing Regulatory Convergence |
| 126 | Lucila Isabel Castro | Pastrana | Systematic review of the impact on tolerability and adherence of non-severe adverse reactions associated with antidepressant treatment in adolescents |
| M Professional development: 1 Education and Qualification in PV | |||
| 66 | Nadja | Jastrebova | Measuring the Impact of Signal Assessment Workshops Using Follow-Up Evaluations |
| 168 | Ryan | Walker | A Global Systematic Landscape Mapping of Postgraduate Taught Pharmacovigilance Programmes |
| 196 | Maria | Quesada-Morua | Design of a Pedagogical Strategy to Improve Awareness of Pharmacovigilance Training in Pharmacy Education |
| 200 | Fernanda | Marfil | Integrating Pharmacovigilance into Early Professional Education of Pharmaceutical Sales Representatives: Experience From a Theoretical–Practical Training Initiative |
| 303 | Walfred | Sanchez Pe–a | From Validation to Application: Pharmacovigilance Knowledge Gaps Identified in Pharmaceutical Industry Professionals Using a Validated Instrument |
| M Professional development: 2 Training and Certification | |||
| 151 | Twaha | Ssebyala | Knowledge Gaps in Pharmacovigilance Quality Management Systems within Low- and Middle-Income Countries NRAs: Addressing Deficiencies through Structured Training Interventions |
| 227 | Yajaira | Quesada | Strengthening Pharmaceutical Services in the Fight Against Antibiotic Resistance |
| 268 | Ryan | Walker | A Global Systematic Landscape Mapping of Online, Open Access Pharmacovigilance Training Opportunities |
| M Professional development: 3 Students involvement | |||
| 30 | Fabiana | Varallo | Integrating International Nonproprietary Names into the teaching of essential medicines selection: an experience report from a WHO/SoINN pilot centre |
| 102 | Jose Alberto | Ayala Ortiz | Building Trust Through Education: The “Aula de Farmacovigilancia” as a Collaborative Academic–Industry Model for Pharmacovigilance Capacity Building |
| 118 | Guillermo | Keller | Assessment of students' knowledge, interest, and experience regarding pharmacovigilance |
| 128 | Onyinye | Akunne | Building a Student Pharmacovigilance Ambassador Network: A Scalable Model for Strengthening Pharmacovigilance Capacity in Nigeria |
| 171 | Fabián | Gamboa | Training the Next Generation in Pharmacovigilance: An Academic–Industry Collaboration in Costa Rica |
| N Miscellaneous: 1 Miscellaneous | |||
| 8 | Jana | Brajdih Čendak | The Atomic Ecosystem of Trust: Expanding Radiopharmaceutical Pharmacovigilance from Patient Safety to Environmental Stewardship |
| 18 | Brahim | Azzouz | Psoriasis following exposure to cardioselective beta-blockers: a safety signal using the WHO pharmacovigilance database. |
| 33 | Nicole | Fornarotto | The Role of The Medical Dictionary for Regulatory Activity (MedDRA) in Semantic Interoperability |
| 81 | Roberto Jesús | Tovar Arrieta | Development and Evaluation of an Information Bulletin from Costa Rica's National Drug Information Center for Health Professionals and Students |
| 122 | Ronald | Kiguba | Characterizing Sexual Dysfunction in Ugandan Men Initiating or Continuing Dolutegravir-Based Antiretroviral Therapy |
| 153 | Fredrik | Brouneus | Evaluating #MedSafetyWeek – a Multi-Country Pilot to Strengthen Pharmacovigilance Campaign Assessment |
| 155 | Oumaima | EL QABISSI | Biotherapies and pharmacovigilance: Data from a University Hospital Center |
| 176 | Zakir | Khan | Recommendations relating to adverse drug withdrawal events in clinical practice guidelines: a secondary analysis of a scoping review |
| 202 | Adela | Ashie | Hemovigilance Implementation in Ghana: Stage 1 Pilot Implementation |
| 215 | Carolina | Hernanadez | Evaluation Of The Degree Of Completeness Of Spontaneous Case Safety Reports Received From The Marketing Authorization Holder |
| 271 | Lincoln | Marques | Exploring Disparities in Pharmacovigilance Data Access: Mapping National Regulatory Authority Data Sharing Practices across Latin America and Caribbean |
| 288 | C. Gelida | Barboza Justiniano | Cosmetics and Public Health: A Surveillance Commitment We Need in Latin American Countries |
| 301 | RACHID ALEXANDER | ELAM AYALA | Teaching–learning experience of pharmacovigilance from the pharmacology course in medical students at a Colombian university |
